TY - JOUR
T1 - Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer
AU - Di Giorgio, Andrea
AU - Santullo, Francesco
AU - Attalla El Halabieh, Miriam
AU - Lodoli, Claudio
AU - Abatini, Carlo
AU - Calegari, Maria Alessandra
AU - Martini, Maurizio
AU - Rotolo, Stefano
AU - Pacelli, Fabio
PY - 2021
Y1 - 2021
N2 - Purpose: Careful patient selection plays a crucial role in avoiding overtreatment and further increases survival rates in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer (CRC) with peritoneal metastases (PM). Methods: The clinical and molecular factors influencing survival in patients who had undergone CRS with HIPEC between January 2015 and December 2018 were analyzed. Results: Sixty-six patients underwent CRS with HIPEC during the study period. The median overall survival (OS) was 36 months, with a 3-year OS of 43%. Multivariate analysis revealed increased PCI (HR: 1.21; 95% CI: 1.02–1.41; p = 0.020), right-sided primary tumor (HR: 3.01; 95% CI: 1.27–7.13; p = 0.017), and BRAF V600E mutation (HR: 4.55; 95% CI: 1.21–17.21; p = 0.025) as independent predictors for worse OS. Conclusion: In addition to confirming the prognostic role of PCI, our study extends the role of BRAF mutation and right primary tumor location as markers for worse prognosis.
AB - Purpose: Careful patient selection plays a crucial role in avoiding overtreatment and further increases survival rates in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer (CRC) with peritoneal metastases (PM). Methods: The clinical and molecular factors influencing survival in patients who had undergone CRS with HIPEC between January 2015 and December 2018 were analyzed. Results: Sixty-six patients underwent CRS with HIPEC during the study period. The median overall survival (OS) was 36 months, with a 3-year OS of 43%. Multivariate analysis revealed increased PCI (HR: 1.21; 95% CI: 1.02–1.41; p = 0.020), right-sided primary tumor (HR: 3.01; 95% CI: 1.27–7.13; p = 0.017), and BRAF V600E mutation (HR: 4.55; 95% CI: 1.21–17.21; p = 0.025) as independent predictors for worse OS. Conclusion: In addition to confirming the prognostic role of PCI, our study extends the role of BRAF mutation and right primary tumor location as markers for worse prognosis.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - BRAF
KW - Colorectal Neoplasms
KW - Colorectal cancer
KW - Combined Modality Therapy
KW - Cytoreduction Surgical Procedures
KW - Cytoreductive surgery (CRS)
KW - Humans
KW - Hyperthermia, Induced
KW - Hyperthermic Intraperitoneal Chemotherapy
KW - Hyperthermic intraperitoneal chemotherapy (HIPEC)
KW - Percutaneous Coronary Intervention
KW - Peritoneal Neoplasms
KW - Peritoneal metastasis
KW - Prognosis
KW - Retrospective Studies
KW - Survival Rate
KW - Antineoplastic Combined Chemotherapy Protocols
KW - BRAF
KW - Colorectal Neoplasms
KW - Colorectal cancer
KW - Combined Modality Therapy
KW - Cytoreduction Surgical Procedures
KW - Cytoreductive surgery (CRS)
KW - Humans
KW - Hyperthermia, Induced
KW - Hyperthermic Intraperitoneal Chemotherapy
KW - Hyperthermic intraperitoneal chemotherapy (HIPEC)
KW - Percutaneous Coronary Intervention
KW - Peritoneal Neoplasms
KW - Peritoneal metastasis
KW - Prognosis
KW - Retrospective Studies
KW - Survival Rate
UR - http://hdl.handle.net/10807/206262
U2 - 10.1007/s11605-021-05073-3
DO - 10.1007/s11605-021-05073-3
M3 - Article
SN - 1091-255X
VL - 25
SP - 2649
EP - 2659
JO - Journal of Gastrointestinal Surgery
JF - Journal of Gastrointestinal Surgery
ER -
